We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

This study has suspended participant recruitment.
(Study completed at site, no active participants. IDE open for future enrollment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01419704
First Posted: August 18, 2011
Last Update Posted: September 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Duke University
Information provided by (Responsible Party):
University of Louisville
  Purpose
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.

Condition Intervention Phase
Anemia, Sickle Cell Complex and Transfusion-dependent Hemoglobinopathies Thalassemia Diamond-Blackfan Anemia Bone Marrow Failure Syndromes Alpha-Thalassemia Beta-Thalassemia Biological: Enriched Hematopoetic Stem Cell Infusion Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

Resource links provided by NLM:


Further study details as provided by University of Louisville:

Primary Outcome Measures:
  • Proportion of Hemoglobin A and S [ Time Frame: one month to three years ]
    Red blood cell contents by hemoglobin electrophoresis


Secondary Outcome Measures:
  • Enriched Hematopoetic Stem Cell Engraftment [ Time Frame: One month to three years ]

Estimated Enrollment: 30
Study Start Date: May 2011
Estimated Study Completion Date: May 2030
Estimated Primary Completion Date: May 2025 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hemoglobinopathies diagnosed patients
Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
Biological: Enriched Hematopoetic Stem Cell Infusion
Enriched Hematopoetic Stem Cell Infusion

Detailed Description:
This proposal is a phase I/II feasibility study to demonstrate that mixed chimerism can be established with minimal risk in recipients with hemoglobinopathies treated with Campath-1H-based nonmyeloablative conditioning and graft engineering to reduce the risk of Graft Versus Host Disease (GVHD), but preserve engraftment of donor cells.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Inclusion Criteria

    The following criteria are established to identify subjects with hemoglobinopathies, hematologic or bone marrow failure syndromes who have a high predicted morbidity and are at risk for early mortality:

    • Patients with alpha or beta thalassemia major.
    • Patients with Diamond-Blackfan anemia and other bone marrow failure syndromes, characterized by severe chronic anemia.
    • Patients with other complex and transfusion-dependent hemoglobinopathies, including sickle cell disease.
    • Patients with sickle disease who have one or more of the following:

      • Overt or silent stroke
      • Neurocognitive impairment
      • Pain crises 2 or more episodes per year for past year
      • One or more episodes of acute chest syndrome
      • Osteonecrosis involving 1 or more joints
      • Evidence of retinopathy
      • Priapism
      • Microalbuminuria or evidence of sickle cell nephropathy
      • Alloimmunization

    Subjects must also meet all of the following general inclusion criteria:

    • Subjects must have a related donor which can consist of Histocompatibility Leukocyte Antigen (HLA)-matched donor up to haploidentical match, mismatched for 1, 2 or 3 HLA-A, B or -DR loci.
    • Subjects must have adequate cardiopulmonary function as documented by echocardiogram or radionuclide scan. (Shortening fraction >26% or ejection fraction >40% or ≥ 80% of normal value for age).
    • Subjects must have adequate pulmonary function documented by Forced expiratory volume in 1 second (FEV1) of ≥ 50% of predicted for age and/or Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ≥50% of predicted for age for patients > 10 years of age.
    • Subjects must have adequate hepatic function as demonstrated by a serum albumin ≥ 3.0 mg/dL, and serum glutamic pyruvic transaminase (SGPT) or serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 5 times the upper limit of normal. Liver biopsy or a liver MRI is necessary if the patient has received chronic transfusions for over a year and/or has a ferritin level of ≥ 1600.
    • Subjects must have adequate renal function as demonstrated by a serum creatinine less than or equal to 2 mg/dL. If serum creatinine is ≥ 2 mg/dL, then a creatinine clearance test or nuclear medicine GFR should document GFR of ≥ 50 ml/min/1.73 m2.
    • Subjects or legal guardians must give written informed consent.
    • Female patients of childbearing potential cannot be pregnant or lactating/breast-feeding and must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the investigator (e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy).
    • Less than or equal to 45 years of age.
  2. Exclusion Criteria

    • Patients with cirrhosis, extensive bridging hepatic fibrosis, or active hepatitis are excluded from enrollment.
    • Uncontrolled infection or severe concomitant diseases, which in the judgment of the Principal Investigator, indicate that the patient could not tolerate reduced intensity transplantation.
    • Severe impairment of functional performance as evidenced by a Karnofsky score <70% (patients ≥16 years old) or Lansky (children <16 years old) score <70%
    • Renal insufficiency (GFR <50 ml/min/1.73 m2).
    • Subjects with a positive human immunodeficiency virus (HIV) antibody test result.
    • Subjects who are pregnant, as indicated by a positive serum human chorionic gonadotrophin (HCG) test.
    • Subjects whose only donor is pregnant at the time of intended transplant.
    • Subjects of childbearing potential who are not practicing adequate contraception as defined by the investigator at the site.
    • Allogeneic hematopoietic stem cell transplant within the previous 1 year.
    • Subjects must not have had previous radiation therapy that would preclude total body irradiation (TBI) (as determined by a radiation therapist).
    • Jehovah's Witness unwilling to be transfused .
    • Uncontrolled hypersplenism.
    • Severe alloimmunization with inability to guarantee a supply of adequate packed red blood cell (PRBC) donors.
    • Subjects with thalassemia who are Lucarelli Class 3
    • Fanconi anemia.
    • Insufficient funds for the bone marrow processing costs
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419704


Locations
United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
University of Louisville
Duke University
Investigators
Study Director: Suzanne T Ildstad, MD University of Louisville
  More Information

Responsible Party: University of Louisville
ClinicalTrials.gov Identifier: NCT01419704     History of Changes
Other Study ID Numbers: ICT-13881-012011
First Submitted: August 16, 2011
First Posted: August 18, 2011
Last Update Posted: September 6, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Louisville:
other hemoglobinopathies
chimerism
sickle cell
thalassemia
Marrow/Enriched Hematopoetic Stem Cell Transplant

Additional relevant MeSH terms:
Anemia
Thalassemia
beta-Thalassemia
Hemoglobinopathies
Pancytopenia
Anemia, Sickle Cell
Anemia, Diamond-Blackfan
Hemoglobinuria, Paroxysmal
alpha-Thalassemia
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn
Anemia, Hypoplastic, Congenital
Anemia, Aplastic
Red-Cell Aplasia, Pure
Bone Marrow Diseases
Myelodysplastic Syndromes


To Top